We read the RCT by Basu et al. [1] with great interest. Reduction in mortality or oxygen requirement in very low birth weight infants by supplementation of a simple, safe, cost-effective oral medication could be of tremendous clinical significance, especially for low-and middle-income countries. Their findings are further strengthened by the higher serum retinol concentrations on day 28 of treatment. However, we wish to raise certain issues and request few clarifications.
The authors assumed a baseline incidence of their primary outcome to be 64% whereas the observed incidence in the placebo group is only 25%. Unfortunately, this has reduced the study's statistical power in detecting a true reduction in the rate of mortality or oxygen requirement at 28 days.
Majority of the deaths in the placebo group seem to have occurred within 7 days of age, as seen in the Kaplan-Meier survival curve. Could this result from not being exposed to vitamin A on alternate days? This also makes us think if there was a potential unmeasured confounder and whether the study groups were comparable at baseline. Adjustment of the primary outcome estimate for the competing risk event (early neonatal death) could have been considered.
We would also be interested to know the number of infants discharged home before 28 days in both groups. Considering that vitamin A supplementation resulted in significant benefits among term neonates in community settings [2] , the efficacy and safety of post-discharge vitamin A therapy in high-risk neonates need to be researched.
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